Form 4: X4 Pharmaceuticals Grants Equity to Chief Legal Officer Natasha Thoren

X4 Pharmaceuticals, Inc. has granted 3,333 restricted stock units to its Chief Legal Officer, Natasha Fay Thoren, as part of the company's equity incentive plan.

Summary

• Natasha Fay Thoren, Chief Legal Officer of X4 Pharmaceuticals, Inc. (XFOR), was granted 3,333 restricted stock units (RSUs) on May 20, 2025.
• The RSUs were granted at a price of $0 and represent the right to receive one share of common stock per unit upon vesting.
• These restricted stock units will vest in three equal annual installments on May 10, 2026, May 10, 2027, and May 10, 2028, contingent on Ms. Thoren's continued employment with the Issuer.
• Following this transaction, Natasha Fay Thoren beneficially owns 9,462 shares of common stock.
• The reported beneficial ownership amount has been adjusted to correct an inadvertent overstatement of 855 shares on a previously filed Form 3 on June 3, 2025.

Sentiment

Score: 6

Explanation: The document reflects a routine executive compensation event, which is generally positive as it aligns management incentives with shareholder interests, without indicating any negative operational or financial news.

Positives

• The grant of restricted stock units aligns the Chief Legal Officer's long-term interests with those of the shareholders, incentivizing performance and retention.
• Equity compensation is a standard practice for executive remuneration, reflecting confidence in the executive's continued contribution.

Negatives

• The grant of restricted stock units, upon vesting and conversion to common stock, will result in a minor dilution of existing shareholder equity.

Risks

• The vesting of the restricted stock units is subject to the Reporting Person continuing to provide service as an employee of the Issuer through the specified vesting dates.

Future Outlook

The restricted stock units are scheduled to vest in three equal annual installments on May 10, 2026, May 10, 2027, and May 10, 2028, subject to the Chief Legal Officer's continued service.

Management Comments

• The grant of restricted stock units was made under the Issuer's Amended and Restated 2017 Equity Incentive Plan.

Industry Context

Equity grants, such as restricted stock units, are a common component of executive compensation packages across various industries, particularly in biotechnology and pharmaceuticals, to attract, retain, and incentivize key talent.

Comparison to Industry Standards

• The grant of restricted stock units with a multi-year vesting schedule is a standard practice for executive compensation in the biotechnology and pharmaceutical sectors, aligning with typical long-term incentive structures seen at comparable companies.
• The $0 grant price for RSUs is standard, as RSUs represent a promise to deliver shares upon vesting, rather than an option to purchase shares.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Natasha Fay Thoren, the Chief Legal Officer, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: The grant of RSUs, upon vesting, will result in minor dilution, but aims to align executive incentives with shareholder value creation.
• Employees: The grant is part of the company's equity incentive plan, which can positively impact employee morale and retention by demonstrating a commitment to long-term incentives for key personnel.

Next Steps

• The restricted stock units will vest in three equal annual installments on May 10, 2026, May 10, 2027, and May 10, 2028, contingent on continued employment.

Key Dates

Keywords

X4 Pharmaceuticals, XFOR, Restricted Stock Units, Equity Grant, SEC Form 4, Beneficial Ownership, Executive Compensation, Natasha Fay Thoren, Chief Legal Officer